What is the drug of choice for motion sickness in children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Drug of Choice for Motion Sickness in Children

Dimenhydrinate is the drug of choice for motion sickness in children due to its established efficacy and safety profile for pediatric use. 1

First-Line Medications

Antihistamines

  • Dimenhydrinate (Dramamine):

    • FDA-approved for prevention and treatment of motion sickness 1
    • Dosing by age:
      • 2-5 years: 12.5-25 mg every 6-8 hours (max 75 mg/day)
      • 6-12 years: 25-50 mg every 6-8 hours (max 150 mg/day)
      • 12 years: 50-100 mg every 4-6 hours (max 400 mg/day)

    • Should be administered 30-60 minutes before travel
  • Meclizine (Antivert):

    • Alternative for children ≥12 years
    • 25-50 mg once daily, 1 hour before travel
    • Not FDA-approved for younger children

Evidence for Efficacy

Antihistamines are probably more effective than placebo at preventing motion sickness symptoms under natural conditions, with a prevention rate of 40% compared to 25% with placebo 2. First-generation antihistamines like dimenhydrinate have demonstrated effectiveness in preventing motion sickness in susceptible individuals 3.

A Cochrane review found moderate-certainty evidence supporting antihistamines for motion sickness prevention, though they may cause sedation more frequently than placebo 2.

Important Considerations

Timing of Administration

  • Administer 30-60 minutes before anticipated motion exposure
  • For longer trips, may need to redose according to duration of action

Side Effects

  • Sedation: Most common side effect (66% with antihistamines vs 44% with placebo) 2
  • Other potential side effects:
    • Dry mouth
    • Blurred vision (14% with antihistamines vs 12.5% with placebo) 2
    • Mild cognitive impairment

Contraindications

  • Children under 2 years (limited safety data)
  • Known hypersensitivity to antihistamines
  • Caution in children with:
    • Narrow-angle glaucoma
    • Bladder neck obstruction
    • Seizure disorders

Non-Pharmacological Approaches

These should be used alongside medication for best results:

  • Position child to minimize motion (middle of car, over wings in airplane)
  • Have child look at the horizon or a fixed point
  • Ensure adequate ventilation
  • Avoid reading or screen time during travel
  • Small, light meals before travel (avoid heavy, spicy, or fatty foods)
  • Regular breaks during travel

Special Populations

Infants and Young Children

  • Limited data on motion sickness in very young children, but it can occur even in infancy 4
  • For children under 2 years, non-pharmacological measures are preferred
  • Consider consulting a pediatrician before using medications in very young children

Children with Comorbidities

  • Children with migraine disorders, vestibular impairment, or history of otitis media may be more susceptible to motion sickness 4
  • These children may benefit from prophylactic treatment before travel

Ineffective Treatments

  • Ondansetron: Not effective for motion sickness prevention despite its antiemetic properties 3, 5
  • Non-sedating antihistamines: Less effective than first-generation antihistamines 3
  • Ginger root: Insufficient evidence for effectiveness in motion sickness 3

Summary

Dimenhydrinate is the most appropriate first-line medication for motion sickness in children, administered 30-60 minutes before travel at age-appropriate doses. Combine with non-pharmacological strategies for optimal prevention. Be aware of potential sedation as the main side effect.

References

Research

Antihistamines for motion sickness.

The Cochrane database of systematic reviews, 2022

Research

Prevention and treatment of motion sickness.

American family physician, 2014

Research

Severe motion sickness in infants and children.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2020

Research

High dose ondansetron for reducing motion sickness in highly susceptible subjects.

Aviation, space, and environmental medicine, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.